Biocryst Pharmaceuticals vs Kiniksa Pharmaceuticals International
Biocryst Pharmaceuticals is the larger business, with $875m of revenue in fiscal 2025 against $678m for Kiniksa Pharmaceuticals International (1.3 times as much). Biocryst Pharmaceuticals grew faster (94.1% against 60.1%). Biocryst Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 30.2% against 8.7%.
| Latest fiscal year | Biocryst PharmaceuticalsBCRX, 2025 | Kiniksa Pharmaceuticals InternationalKNSA, 2025 |
|---|---|---|
| Revenue | $875m | $678m |
| Revenue growth | 94.1% | 60.1% |
| Net income | $264m | $59.0m |
| Operating margin | 39.0% | 11.4% |
| Net margin | 30.2% | 8.7% |
| Return on equity | — | 11.7% |
| Free cash flow | $345m | $136m |
| Cash | $89.7m | $166m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 435 | 366 |
| Market value | $2.19bn | $7.91bn |
| Price vs our value range | Below our value range | Above our value range |
| Moat score | 46 (Moderate) | 16 (Weak) |
| Insider trades, 12 months | 0 buys, 10 sales | 0 buys, 37 sales |